Tags

Type your tag names separated by a space and hit enter

In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Antimicrob Agents Chemother. 2011 Apr; 55(4):1594-7.AA

Abstract

The in vitro and in vivo activities of modithromycin, a novel bicyclolide, against Legionella pneumophila were compared with those of telithromycin, clarithromycin, azithromycin, and levofloxacin. All the test agents decreased the intracellular growth of viable L. pneumophila bacteria over 96 h of incubation in both types of cells used, A/J mouse-derived macrophages and A549 human alveolar epithelial cells, at extracellular concentrations of 4× and 16× MIC, respectively. However, when the agents were removed from the medium after exposure for 2 h, regrowth of intracellular bacteria occurred in both cell systems when they were exposed to telithromycin, clarithromycin, and levofloxacin but not when they were exposed to modithromycin and azithromycin. Once-daily administration of modithromycin at a dose of 10 mg/kg of body weight for 5 days led to a significant decrease of intrapulmonary viable L. pneumophila bacteria in immunosuppressed A/J mice. The efficacy of modithromycin was superior to the efficacies of telithromycin and clarithromycin and comparable to the efficacies of azithromycin and levofloxacin. In addition, modithromycin and azithromycin inhibited the intrapulmonary regrowth of bacteria even at 72 h after the last treatment, but telithromycin and levofloxacin did not. These results suggested that modithromycin has longer-lasting cellular pharmacokinetic features like azithromycin. In conclusion, modithromycin, as well as azithromycin, has excellent in vitro and in vivo bactericidal activities and persistent efficacy against intracellular L. pneumophila. Modithromycin should be a useful agent for treatment of pulmonary infections caused by this pathogen.

Authors+Show Affiliations

Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Ota-ku, Tokyo 143-8540, Japan. takafumi.satou@shionogi.co.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21220530

Citation

Sato, Takafumi, et al. "In Vitro Intracellular Activity and in Vivo Efficacy of Modithromycin, a Novel Bicyclolide, Against Legionella Pneumophila." Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, 2011, pp. 1594-7.
Sato T, Tateda K, Kimura S, et al. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. Antimicrob Agents Chemother. 2011;55(4):1594-7.
Sato, T., Tateda, K., Kimura, S., Ishii, Y., & Yamaguchi, K. (2011). In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. Antimicrobial Agents and Chemotherapy, 55(4), 1594-7. https://doi.org/10.1128/AAC.01474-10
Sato T, et al. In Vitro Intracellular Activity and in Vivo Efficacy of Modithromycin, a Novel Bicyclolide, Against Legionella Pneumophila. Antimicrob Agents Chemother. 2011;55(4):1594-7. PubMed PMID: 21220530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. AU - Sato,Takafumi, AU - Tateda,Kazuhiro, AU - Kimura,Soichiro, AU - Ishii,Yoshikazu, AU - Yamaguchi,Keizo, Y1 - 2011/01/10/ PY - 2011/1/12/entrez PY - 2011/1/12/pubmed PY - 2011/7/16/medline SP - 1594 EP - 7 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 55 IS - 4 N2 - The in vitro and in vivo activities of modithromycin, a novel bicyclolide, against Legionella pneumophila were compared with those of telithromycin, clarithromycin, azithromycin, and levofloxacin. All the test agents decreased the intracellular growth of viable L. pneumophila bacteria over 96 h of incubation in both types of cells used, A/J mouse-derived macrophages and A549 human alveolar epithelial cells, at extracellular concentrations of 4× and 16× MIC, respectively. However, when the agents were removed from the medium after exposure for 2 h, regrowth of intracellular bacteria occurred in both cell systems when they were exposed to telithromycin, clarithromycin, and levofloxacin but not when they were exposed to modithromycin and azithromycin. Once-daily administration of modithromycin at a dose of 10 mg/kg of body weight for 5 days led to a significant decrease of intrapulmonary viable L. pneumophila bacteria in immunosuppressed A/J mice. The efficacy of modithromycin was superior to the efficacies of telithromycin and clarithromycin and comparable to the efficacies of azithromycin and levofloxacin. In addition, modithromycin and azithromycin inhibited the intrapulmonary regrowth of bacteria even at 72 h after the last treatment, but telithromycin and levofloxacin did not. These results suggested that modithromycin has longer-lasting cellular pharmacokinetic features like azithromycin. In conclusion, modithromycin, as well as azithromycin, has excellent in vitro and in vivo bactericidal activities and persistent efficacy against intracellular L. pneumophila. Modithromycin should be a useful agent for treatment of pulmonary infections caused by this pathogen. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/21220530/In_vitro_intracellular_activity_and_in_vivo_efficacy_of_modithromycin_a_novel_bicyclolide_against_Legionella_pneumophila_ L2 - https://journals.asm.org/doi/10.1128/AAC.01474-10?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -